| Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases GN Hortobagyi, RL Theriault, L Porter, D Blayney, A Lipton, C Sinoff, ... New England Journal of Medicine 335 (24), 1785-1792, 1996 | 1258 | 1996 |
| Intertumoral heterogeneity within medulloblastoma subgroups FMG Cavalli, M Remke, L Rampasek, J Peacock, DJH Shih, B Luu, ... Cancer cell 31 (6), 737-754. e6, 2017 | 1043 | 2017 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 950 | 2017 |
| Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. GN Hortobagyi, RL Theriault, A Lipton, L Porter, D Blayney, C Sinoff, ... Journal of Clinical Oncology 16 (6), 2038-2044, 1998 | 823 | 1998 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 475 | 2021 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 364 | 2017 |
| Divergent clonal selection dominates medulloblastoma at recurrence AS Morrissy, L Garzia, DJH Shih, S Zuyderduyn, X Huang, P Skowron, ... Nature 529 (7586), 351-357, 2016 | 344 | 2016 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 317 | 2021 |
| Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized … GD Perkins, C Ji, BA Connolly, K Couper, R Lall, JK Baillie, JM Bradley, ... Jama 327 (6), 546-558, 2022 | 294 | 2022 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 286 | 2022 |
| Molecular heterogeneity in glioblastoma: potential clinical implications NR Parker, P Khong, JF Parkinson, VM Howell, HR Wheeler Frontiers in oncology 5, 55, 2015 | 279 | 2015 |
| A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma AA Brandes, AF Carpentier, S Kesari, JM Sepulveda-Sanchez, ... Neuro-oncology 18 (8), 1146-1156, 2016 | 234 | 2016 |
| Glioma progression is shaped by genetic evolution and microenvironment interactions FS Varn, KC Johnson, J Martinek, JT Huse, MLP Nasrallah, P Wesseling, ... Cell 185 (12), 2184-2199. e16, 2022 | 190 | 2022 |
| Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis V Ramaswamy, T Hielscher, SC Mack, A Lassaletta, T Lin, KW Pajtler, ... Journal of Clinical Oncology 34 (21), 2468, 2016 | 188 | 2016 |
| Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 … MJ van den Bent, CMS Tesileanu, W Wick, M Sanson, AA Brandes, ... The Lancet Oncology 22 (6), 813-823, 2021 | 174 | 2021 |
| Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma NR Parker, AL Hudson, P Khong, JF Parkinson, T Dwight, RJ Ikin, Y Zhu, ... Scientific reports 6 (1), 22477, 2016 | 173 | 2016 |
| Antiangiogenic therapy for high‐grade glioma M Khasraw, MS Ameratunga, R Grant, H Wheeler, N Pavlakis Cochrane Database of Systematic Reviews, 2014 | 160 | 2014 |
| miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion A Fowler, D Thomson, K Giles, S Maleki, E Mreich, H Wheeler, ... European journal of cancer 47 (6), 953-963, 2011 | 157 | 2011 |
| Teamwork on inpatient medical units: assessing attitudes and barriers KJ O'Leary, CD Ritter, H Wheeler, MK Szekendi, TS Brinton, MV Williams BMJ Quality & Safety 19 (2), 117-121, 2010 | 156 | 2010 |
| Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma KM Field, J Simes, AK Nowak, L Cher, H Wheeler, EJ Hovey, CSB Brown, ... Neuro-oncology 17 (11), 1504-1513, 2015 | 149 | 2015 |
